EQT to sell Ellab to Novo Holdings
Today, EQT announced they have agreed to sell Ellab to Novo Holdings, a leading global life sciences investor.
Ellab’s portfolio of high-quality offerings for the pharma and biotech sector aligns perfectly with Novo Holdings investment focus and expertise, and Novo Holdings will support the continued growth of Ellab, building on the impressive long-standing track-record, by utilizing its industry network and global presence to accelerate future business expansion.
CEO of Ellab A/S, Ludvig Enlund commented:
“Today is a proud day for Ellab. Our company has seen tremendous growth under EQT’s ownership; tripling our revenue, EBITDA and number of employees, and this transaction is a culmination of that. We have been grateful for the partnership with EQT and now look forward to continuing our journey with Novo Holdings to ensure the continued success of Ellab and our long-term strategy”.
Financial terms of the transaction are not disclosed. The transaction is subject to regulatory approval, and closing of the transaction is expected in Q3 2023.
From left to right: Ludvig Enlund, CEO at Ellab, Andreas Morthorst, CFO at Ellab
For further information, please contact:
Jan Fledelius, Vice President, Global HR & Communications, phone
+45 42460200 or email@example.com